Kbc Group Nv Seres Therapeutics, Inc. Transaction History

Kbc Group Nv

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$6.02 - $11.43 $31,544 - $59,893	-5,240 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$5.46 - $22.6 $2,184 - $9,040	-400 Reduced 7.09%	5,240 $36,000
Q2 2021 Aug 11, 2021	BUY	$18.46 - $24.36 $90,454 - $119,364	4,900 Added 662.16%	5,640 $135,000
Q4 2020 Feb 10, 2021	SELL	$23.25 - $37.73 $6,975 - $11,318	-300 Reduced 28.85%	740 $18,000
Q3 2020 Oct 28, 2020	SELL	$3.74 - $28.74 $23,749 - $182,499	-6,350 Reduced 85.93%	1,040 $29,000
Q2 2020 Aug 10, 2020	SELL	$3.04 - $6.2 $9,150 - $18,662	-3,010 Reduced 28.94%	7,390 $35,000
Q4 2019 Feb 11, 2020	BUY	$2.99 - $4.42 $30,692 - $45,371	10,265 Added 7603.7%	10,400 $36,000
Q2 2019 Dec 03, 2019	BUY	$2.28 - $7.35 $307 - $992	135 New	135 $1,000

40.5M

304K

471K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $95.5M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.